100 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
with GLP-1 therapeutics to manage their type 2 diabetes.
Our Strategy
Our goal is to become a leading biotechnology company focused on developing … components of our strategy are to:
Advance EFX through clinical development in both pre-cirrhotic (F2-F3) and cirrhotic (F4, compensated) MASH. We believe
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
clinical trials; Akero’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
Vice President, Commercial Strategy
William White, J.D.
Mr. White has served as our Executive Vice President, Chief Financial Officer and Head … served as our Senior Vice President of Commercial Strategy since January 2023. Before joining the Company, Mr. Lamy provided commercial strategy
8-K
EX-99.1
ev3vc15 jq
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
un29onq
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
b5id55p mq2lbu4ss7x
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
d2dyazjipytxg tu6
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
9yizcsyzty bhm1
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
b8f4 6exyreapa2j8
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
hxeb bqvn
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
3ck3r1bg4 jcnpr
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.2
am0hgg l1
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
3340stwrmd0r
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
EX-99.1
40gvfk7367o586
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
gwnhn9y5pbvb
5 Jun 23
Results of Operations and Financial Condition
8:05am